Lemoxol

Ceftazidime, the active ingredient in Lemoxol, is a third‑generation cephalosporin presented as a parenteral solution for intramuscular and intravenous use. It treats severe infections caused by susceptible gram‑negative bacteria, including Pseudomonas aeruginosa, in hospitalized patients.

GNH USA supplies Lemoxol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ceftazidime is a third‑generation cephalosporin antibiotic used to treat infections caused by susceptible gram‑negative bacteria. - Hospital‑acquired pneumonia: effective in reducing bacterial load and improving clinical outcomes. - Complicated urinary tract infections: eradicates causative gram‑negative pathogens. - Intra‑abdominal infections: provides coverage against aerobic and anaerobic organisms. - Pseudomonas aeruginosa infections: active against resistant strains in severe cases. - Severe sepsis caused by susceptible organisms: supports systemic infection control.

Ceftazidime may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Diarrhea: loose, sometimes watery stools. - Injection site pain: local discomfort or erythema. - Rash: mild skin eruption.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with respiratory distress. - Clostridioides difficile colitis: severe diarrhea due to bacterial overgrowth. - Neutropenia: marked reduction in neutrophil count. - Renal impairment: worsening kidney function, especially with high doses.

When using Ceftazidime, clinicians should consider several safety precautions. - Assess renal function: dose adjustment may be required in impaired kidneys. - Monitor for allergic reactions: discontinue if signs of hypersensitivity appear. - Evaluate hepatic status: liver disease may affect drug clearance. - Use caution in neonates and infants: higher risk of bilirubin displacement. - Avoid concomitant nephrotoxic drugs: increased risk of kidney injury. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze.

Ceftazidime can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Aminoglycosides: combined use can increase nephrotoxicity. - Loop diuretics: may potentiate renal impairment. - Probenecid: decreases renal clearance, raising ceftazidime concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Oral contraceptives: possible reduction in efficacy, consider additional contraception. - Methotrexate: concurrent use may increase methotrexate toxicity.